# Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT03391466** · PHASE3 · COMPLETED · sponsor: **Kite, A Gilead Company** · enrollment: 359 (actual)

## Conditions studied

- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel
- **DRUG:** Platinum-containing Salvage Chemotherapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT03391466
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-25
- **Primary completion:** 2021-03-18
- **Final completion:** 2024-11-25
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2025-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03391466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03391466, "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT03391466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*